Globus Medical Inc. Class A Common Stock vs Nuscale Power Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Nuscale Power Corporation trades at $5.75 (market cap $2.75B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.7× Nuscale Power Corporation's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Nuscale Power Corporation for 30 Days on average.
| GMED | SMR | |
|---|---|---|
Market Cap | $10.25B | $2.75B |
Volume | 1,108,124 | 40,865,576 |
Sector | Health | Industrials |
52-Week High | $96.82 | $53.43 |
52-Week Low | $58.33 | $5.83 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $9.76B | $1.68B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NuScale Power (SMR) trades at $6.495, down 3.06% on the day, reflecting ongoing operational losses and negative investor sentiment. The stock exhibits a bearish technical signal, with moving averages indicating strong selling pressure, though oversold oscillators suggest potential for a near-term bounce. Fundamentally, the company reported a net loss of $355.79M on revenue of $31.48M in 2025, with a deeply negative net income margin of -3,888.7% in 2026, highlighting severe profitability challenges despite operating in the high-potential nuclear energy sector.
The outlook remains highly speculative. Analyst consensus is a 'Buy' with a $11.25 price target, implying significant upside, but this is contingent on successful commercialization of its small modular reactor technology. Primary risks include persistent cash burn, intense competition, and the high capital and regulatory hurdles inherent in nuclear power development. The stock represents a high-risk, high-reward opportunity for investors betting on a future nuclear renaissance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →